BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

837 related articles for article (PubMed ID: 22219182)

  • 21. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
    Li L; Karanika S; Yang G; Wang J; Park S; Broom BM; Manyam GC; Wu W; Luo Y; Basourakos S; Song JH; Gallick GE; Karantanos T; Korentzelos D; Azad AK; Kim J; Corn PG; Aparicio AM; Logothetis CJ; Troncoso P; Heffernan T; Toniatti C; Lee HS; Lee JS; Zuo X; Chang W; Yin J; Thompson TC
    Sci Signal; 2017 May; 10(480):. PubMed ID: 28536297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MORC2 regulates DNA damage response through a PARP1-dependent pathway.
    Zhang L; Li DQ
    Nucleic Acids Res; 2019 Sep; 47(16):8502-8520. PubMed ID: 31616951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PARP-2 depletion results in lower radiation cell survival but cell line-specific differences in poly(ADP-ribose) levels.
    Boudra MT; Bolin C; Chiker S; Fouquin A; Zaremba T; Vaslin L; Biard D; Cordelières FP; Mégnin-Chanet F; Favaudon V; Fernet M; Pennaneach V; Hall J
    Cell Mol Life Sci; 2015 Apr; 72(8):1585-97. PubMed ID: 25336152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1.
    Ahel D; Horejsí Z; Wiechens N; Polo SE; Garcia-Wilson E; Ahel I; Flynn H; Skehel M; West SC; Jackson SP; Owen-Hughes T; Boulton SJ
    Science; 2009 Sep; 325(5945):1240-3. PubMed ID: 19661379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.
    Wang L; Yang C; Xie C; Jiang J; Gao M; Fu L; Li Y; Bao X; Fu H; Lou L
    Cancer Sci; 2019 Mar; 110(3):1064-1075. PubMed ID: 30663191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A PARP1-BRG1-SIRT1 axis promotes HR repair by reducing nucleosome density at DNA damage sites.
    Chen Y; Zhang H; Xu Z; Tang H; Geng A; Cai B; Su T; Shi J; Jiang C; Tian X; Seluanov A; Huang J; Wan X; Jiang Y; Gorbunova V; Mao Z
    Nucleic Acids Res; 2019 Sep; 47(16):8563-8580. PubMed ID: 31291457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple roles of BRIT1/MCPH1 in DNA damage response, DNA repair, and cancer suppression.
    Lin SY; Liang Y; Li K
    Yonsei Med J; 2010 May; 51(3):295-301. PubMed ID: 20376879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibiting the MCM8-9 complex selectively sensitizes cancer cells to cisplatin and olaparib.
    Morii I; Iwabuchi Y; Mori S; Suekuni M; Natsume T; Yoshida K; Sugimoto N; Kanemaki MT; Fujita M
    Cancer Sci; 2019 Mar; 110(3):1044-1053. PubMed ID: 30648820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma.
    Nio K; Yamashita T; Okada H; Kondo M; Hayashi T; Hara Y; Nomura Y; Zeng SS; Yoshida M; Hayashi T; Sunagozaka H; Oishi N; Honda M; Kaneko S
    J Hepatol; 2015 Nov; 63(5):1164-72. PubMed ID: 26095183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
    Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
    Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poly(ADP-ribose) contributes to an association between poly(ADP-ribose) polymerase-1 and xeroderma pigmentosum complementation group A in nucleotide excision repair.
    King BS; Cooper KL; Liu KJ; Hudson LG
    J Biol Chem; 2012 Nov; 287(47):39824-33. PubMed ID: 23038248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.
    Gottipati P; Vischioni B; Schultz N; Solomons J; Bryant HE; Djureinovic T; Issaeva N; Sleeth K; Sharma RA; Helleday T
    Cancer Res; 2010 Jul; 70(13):5389-98. PubMed ID: 20551068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells.
    Fathers C; Drayton RM; Solovieva S; Bryant HE
    Cell Cycle; 2012 Mar; 11(5):990-7. PubMed ID: 22333589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option.
    Pessetto ZY; Yan Y; Bessho T; Natarajan A
    Breast Cancer Res Treat; 2012 Jul; 134(2):511-7. PubMed ID: 22562176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.
    Frankum J; Moudry P; Brough R; Hodny Z; Ashworth A; Bartek J; Lord CJ
    Oncotarget; 2015 May; 6(13):10746-58. PubMed ID: 25883215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. iTRAQ-based chromatin proteomic screen reveals CHD4-dependent recruitment of MBD2 to sites of DNA damage.
    Sun Y; Yang Y; Shen H; Huang M; Wang Z; Liu Y; Zhang H; Tang TS; Guo C
    Biochem Biophys Res Commun; 2016 Feb; 471(1):142-8. PubMed ID: 26827827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.